A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China
This study aimed to evaluate the efficacy of the CCCG-B-NHL 2010 protocol in children with mature B-cell non-Hodgkin's lymphoma (B-NHL) in China retrospectively. Eight tertiary referral centers for childhood cancer participated in this study. From April 2009 to March 2012, 104 patients below 18...
Gespeichert in:
| Veröffentlicht in: | Zhonghua er ke za zhi 2014-09, Vol.52 (9), p.649-654 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 654 |
|---|---|
| container_issue | 9 |
| container_start_page | 649 |
| container_title | Zhonghua er ke za zhi |
| container_volume | 52 |
| creator | Committee of Pediatrics, Chinese Anti-Cancer Association Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association Committee of Pediatrics Chinese Anti-Cancer Association |
| description | This study aimed to evaluate the efficacy of the CCCG-B-NHL 2010 protocol in children with mature B-cell non-Hodgkin's lymphoma (B-NHL) in China retrospectively.
Eight tertiary referral centers for childhood cancer participated in this study. From April 2009 to March 2012, 104 patients below 18 years with newly diagnosed, untreated B-NHL or mature B cell acute lymphoblastic leukemia (B-ALL) were enrolled. Six patients refused further staging work-up and treatment due to the expense were excluded. Diagnostic slides were not centrally reviewed in this retrospective study. Twenty-three of 104 patients got rituximab therapy during the treatment.
Of the 104 eligible patients (79 boys and 25 girls), the median age was 6.1 years (range 1.8-15.1 years). Two patients (1.9%) had stage I disease, 22 (21.2%) had stage II, 65 (62.5%) had stage III, 9 (8.6%) had stage IV, and 6 (5.8%) had B-ALL. At a median follow-up of 27.9 months (range 4.2-51.5 months), the 2-year probability of event-free survival (EFS) was (76.0 ± 4.3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1634281629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1634281629</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-a1da6aecc7e08fc7324071f725da66682c124bb00d61502767cac77bfa9833f43</originalsourceid><addsrcrecordid>eNo1kE9LwzAchnNQ3Jj7CpKbXgL516Q7zqFuMPAyz-XXJLXBNKlNq_TbO3GeXnh5eHh5r9CSFrokTDC6QOucfU2FkpJTKW7QghdSK8mLJTptsUkhQJ0GGP2Xw3mc7IxTxKb1wQ4u4m8_triDcRocfiTGhYBjimSf7PuHj_cZh7nr29QB9hHvWh_hFl03ELJbX3KF3p6fTrs9Ob6-HHbbI-kZVyMBZkGBM0Y7WjZGCy6pZo3mxblXquSGcVnXlFrFCsq10gaM1nUDm1KIRooVevjz9kP6nFweq87n34EQXZpyxZSQvGSKb87o3QWd6s7Zqh98B8Nc_T8hfgCBNFlm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634281629</pqid></control><display><type>article</type><title>A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Committee of Pediatrics, Chinese Anti-Cancer Association ; Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association ; Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association ; Committee of Pediatrics Chinese Anti-Cancer Association</creator><creatorcontrib>Committee of Pediatrics, Chinese Anti-Cancer Association ; Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association ; Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association ; Committee of Pediatrics Chinese Anti-Cancer Association</creatorcontrib><description>This study aimed to evaluate the efficacy of the CCCG-B-NHL 2010 protocol in children with mature B-cell non-Hodgkin's lymphoma (B-NHL) in China retrospectively.
Eight tertiary referral centers for childhood cancer participated in this study. From April 2009 to March 2012, 104 patients below 18 years with newly diagnosed, untreated B-NHL or mature B cell acute lymphoblastic leukemia (B-ALL) were enrolled. Six patients refused further staging work-up and treatment due to the expense were excluded. Diagnostic slides were not centrally reviewed in this retrospective study. Twenty-three of 104 patients got rituximab therapy during the treatment.
Of the 104 eligible patients (79 boys and 25 girls), the median age was 6.1 years (range 1.8-15.1 years). Two patients (1.9%) had stage I disease, 22 (21.2%) had stage II, 65 (62.5%) had stage III, 9 (8.6%) had stage IV, and 6 (5.8%) had B-ALL. At a median follow-up of 27.9 months (range 4.2-51.5 months), the 2-year probability of event-free survival (EFS) was (76.0 ± 4.3</description><identifier>ISSN: 0578-1310</identifier><identifier>PMID: 25476425</identifier><language>chi</language><publisher>China</publisher><subject>Adolescent ; Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Child, Preschool ; China ; Cooperative Behavior ; Disease-Free Survival ; Female ; Humans ; Infant ; Lymphoma, B-Cell - drug therapy ; Male ; Neoplasm Staging ; Retrospective Studies ; Rituximab ; Treatment Outcome</subject><ispartof>Zhonghua er ke za zhi, 2014-09, Vol.52 (9), p.649-654</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25476425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Committee of Pediatrics, Chinese Anti-Cancer Association</creatorcontrib><creatorcontrib>Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association</creatorcontrib><creatorcontrib>Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association</creatorcontrib><creatorcontrib>Committee of Pediatrics Chinese Anti-Cancer Association</creatorcontrib><title>A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China</title><title>Zhonghua er ke za zhi</title><addtitle>Zhonghua Er Ke Za Zhi</addtitle><description>This study aimed to evaluate the efficacy of the CCCG-B-NHL 2010 protocol in children with mature B-cell non-Hodgkin's lymphoma (B-NHL) in China retrospectively.
Eight tertiary referral centers for childhood cancer participated in this study. From April 2009 to March 2012, 104 patients below 18 years with newly diagnosed, untreated B-NHL or mature B cell acute lymphoblastic leukemia (B-ALL) were enrolled. Six patients refused further staging work-up and treatment due to the expense were excluded. Diagnostic slides were not centrally reviewed in this retrospective study. Twenty-three of 104 patients got rituximab therapy during the treatment.
Of the 104 eligible patients (79 boys and 25 girls), the median age was 6.1 years (range 1.8-15.1 years). Two patients (1.9%) had stage I disease, 22 (21.2%) had stage II, 65 (62.5%) had stage III, 9 (8.6%) had stage IV, and 6 (5.8%) had B-ALL. At a median follow-up of 27.9 months (range 4.2-51.5 months), the 2-year probability of event-free survival (EFS) was (76.0 ± 4.3</description><subject>Adolescent</subject><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>China</subject><subject>Cooperative Behavior</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><issn>0578-1310</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE9LwzAchnNQ3Jj7CpKbXgL516Q7zqFuMPAyz-XXJLXBNKlNq_TbO3GeXnh5eHh5r9CSFrokTDC6QOucfU2FkpJTKW7QghdSK8mLJTptsUkhQJ0GGP2Xw3mc7IxTxKb1wQ4u4m8_triDcRocfiTGhYBjimSf7PuHj_cZh7nr29QB9hHvWh_hFl03ELJbX3KF3p6fTrs9Ob6-HHbbI-kZVyMBZkGBM0Y7WjZGCy6pZo3mxblXquSGcVnXlFrFCsq10gaM1nUDm1KIRooVevjz9kP6nFweq87n34EQXZpyxZSQvGSKb87o3QWd6s7Zqh98B8Nc_T8hfgCBNFlm</recordid><startdate>201409</startdate><enddate>201409</enddate><creator>Committee of Pediatrics, Chinese Anti-Cancer Association</creator><creator>Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association</creator><creator>Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association</creator><creator>Committee of Pediatrics Chinese Anti-Cancer Association</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201409</creationdate><title>A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-a1da6aecc7e08fc7324071f725da66682c124bb00d61502767cac77bfa9833f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>China</topic><topic>Cooperative Behavior</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Committee of Pediatrics, Chinese Anti-Cancer Association</creatorcontrib><creatorcontrib>Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association</creatorcontrib><creatorcontrib>Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association</creatorcontrib><creatorcontrib>Committee of Pediatrics Chinese Anti-Cancer Association</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhonghua er ke za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><aucorp>Committee of Pediatrics, Chinese Anti-Cancer Association</aucorp><aucorp>Subspecialty Group of Hematology the Society of Pediatrics Chinese Medical Association</aucorp><aucorp>Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association</aucorp><aucorp>Committee of Pediatrics Chinese Anti-Cancer Association</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China</atitle><jtitle>Zhonghua er ke za zhi</jtitle><addtitle>Zhonghua Er Ke Za Zhi</addtitle><date>2014-09</date><risdate>2014</risdate><volume>52</volume><issue>9</issue><spage>649</spage><epage>654</epage><pages>649-654</pages><issn>0578-1310</issn><abstract>This study aimed to evaluate the efficacy of the CCCG-B-NHL 2010 protocol in children with mature B-cell non-Hodgkin's lymphoma (B-NHL) in China retrospectively.
Eight tertiary referral centers for childhood cancer participated in this study. From April 2009 to March 2012, 104 patients below 18 years with newly diagnosed, untreated B-NHL or mature B cell acute lymphoblastic leukemia (B-ALL) were enrolled. Six patients refused further staging work-up and treatment due to the expense were excluded. Diagnostic slides were not centrally reviewed in this retrospective study. Twenty-three of 104 patients got rituximab therapy during the treatment.
Of the 104 eligible patients (79 boys and 25 girls), the median age was 6.1 years (range 1.8-15.1 years). Two patients (1.9%) had stage I disease, 22 (21.2%) had stage II, 65 (62.5%) had stage III, 9 (8.6%) had stage IV, and 6 (5.8%) had B-ALL. At a median follow-up of 27.9 months (range 4.2-51.5 months), the 2-year probability of event-free survival (EFS) was (76.0 ± 4.3</abstract><cop>China</cop><pmid>25476425</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0578-1310 |
| ispartof | Zhonghua er ke za zhi, 2014-09, Vol.52 (9), p.649-654 |
| issn | 0578-1310 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_1634281629 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Adolescent Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Child Child, Preschool China Cooperative Behavior Disease-Free Survival Female Humans Infant Lymphoma, B-Cell - drug therapy Male Neoplasm Staging Retrospective Studies Rituximab Treatment Outcome |
| title | A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A29%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20collaborative%20study%20on%20children%20with%20mature%20B-cell%20non-Hodgkin's%20lymphoma%20in%20China&rft.jtitle=Zhonghua%20er%20ke%20za%20zhi&rft.aucorp=Committee%20of%20Pediatrics,%20Chinese%20Anti-Cancer%20Association&rft.date=2014-09&rft.volume=52&rft.issue=9&rft.spage=649&rft.epage=654&rft.pages=649-654&rft.issn=0578-1310&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1634281629%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1634281629&rft_id=info:pmid/25476425&rfr_iscdi=true |